Merit Medical Systems, Inc. (NASDAQ:MMSI) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 17.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 165,344 shares of the medical instruments supplier's stock after purchasing an additional 24,528 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.28% of Merit Medical Systems worth $15,992,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. NewSquare Capital LLC purchased a new stake in shares of Merit Medical Systems during the 4th quarter valued at approximately $32,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Merit Medical Systems during the fourth quarter worth $52,000. Federated Hermes Inc. increased its stake in Merit Medical Systems by 139.1% during the fourth quarter. Federated Hermes Inc. now owns 655 shares of the medical instruments supplier's stock worth $63,000 after acquiring an additional 381 shares during the last quarter. Group One Trading LLC purchased a new stake in Merit Medical Systems in the fourth quarter valued at $77,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Merit Medical Systems by 237.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,388 shares of the medical instruments supplier's stock valued at $134,000 after purchasing an additional 977 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Stock Down 1.5%

Merit Medical Systems stock traded down $1.39 during trading on Monday, reaching $93.64. The stock had a trading volume of 482,816 shares, compared to its average volume of 524,124. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. Merit Medical Systems, Inc. has a 52-week low of $80.02 and a 52-week high of $111.45. The stock has a market cap of $5.53 billion, a PE ratio of 45.90, a P/E/G ratio of 2.34 and a beta of 0.70. The business has a 50 day moving average price of $95.56 and a 200 day moving average price of $100.16.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.75 by $0.11. The business had revenue of $355.35 million for the quarter, compared to analyst estimates of $352.57 million. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The company's revenue was up 9.8% on a year-over-year basis. During the same period last year, the business earned $0.77 EPS. On average, analysts predict that Merit Medical Systems, Inc. will post 3.37 EPS for the current year.

Insider Activity at Merit Medical Systems

In related news, CEO Fred P. Lampropoulos sold 31,320 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the transaction, the chief executive officer now owns 1,086,028 shares in the company, valued at $112,794,868.08. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director F. Ann Millner sold 21,250 shares of Merit Medical Systems stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $96.47, for a total value of $2,049,987.50. Following the completion of the sale, the director now directly owns 34,543 shares in the company, valued at $3,332,363.21. This represents a 38.09% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 107,931 shares of company stock valued at $10,875,975 over the last quarter. 3.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

MMSI has been the topic of several research analyst reports. Robert W. Baird reduced their price objective on shares of Merit Medical Systems from $111.00 to $110.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Canaccord Genuity Group set a $112.00 price objective on Merit Medical Systems and gave the company a "buy" rating in a report on Wednesday, May 21st. Wells Fargo & Company restated an "overweight" rating and set a $108.00 target price (up from $106.00) on shares of Merit Medical Systems in a report on Wednesday, May 21st. JPMorgan Chase & Co. initiated coverage on Merit Medical Systems in a research report on Friday, March 28th. They issued an "overweight" rating and a $120.00 target price for the company. Finally, Piper Sandler reissued an "overweight" rating and issued a $110.00 price objective (up previously from $106.00) on shares of Merit Medical Systems in a research note on Friday, May 23rd. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $109.11.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.